Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.

Autor:	Mittempergher L; Research and Development, Agendia N.V., Science Park 406, 1098 XH Amsterdam, The Netherlands., Delahaye LJ; Research and Development, Agendia N.V., Science Park 406, 1098 XH Amsterdam, The Netherlands., Witteveen AT; Research and Development, Agendia N.V., Science Park 406, 1098 XH Amsterdam, The Netherlands., Snel MH; Research and Development, Agendia N.V., Science Park 406, 1098 XH Amsterdam, The Netherlands., Mee S; Product Support, Agendia Inc., 22 Morgan, Irvine, CA 92780, USA., Chan BY; Product Support, Agendia Inc., 22 Morgan, Irvine, CA 92780, USA., Dreezen C; Research and Development, Agendia N.V., Science Park 406, 1098 XH Amsterdam, The Netherlands., Besseling N; Research and Development, Agendia N.V., Science Park 406, 1098 XH Amsterdam, The Netherlands., Luiten EJ; Department of Surgery, Amphia Hospital, Molengracht 21, 4818 CK, Breda, The Netherlands.
Jazyk:	angličtina
Zdroj:	Translational oncology [Transl Oncol] 2020 Apr; Vol. 13 (4), pp. 100756. Date of Electronic Publication: 2020 Mar 21.
DOI:	10.1016/j.tranon.2020.100756
Abstrakt:	The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes. (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu